Drug profile · INN
talazoparib
TALZENNA
talazoparib (TALZENNA) is a poly [adp-ribose] polymerase 2 inhibitor. Associated with Pfizer Australia Pty Ltd.
Drug details — talazoparib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 2
- Programs
- 8
- Data quality
- 0.83
Quick answer
talazoparib (TALZENNA) is a poly [adp-ribose] polymerase 2 inhibitor. Associated with Pfizer Australia Pty Ltd.
Key facts
Mechanism of action
Poly [ADP-ribose] polymerase 2 inhibitor
Primary target: Poly [ADP-ribose] polymerase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Recent coverage
Pfizer sharpens prostate cancer case with Talzenna win — oncology
Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.
Pfizer's Talzenna Combo: A Game Changer in Prostate Cancer Treatment
Pfizer has made significant strides with its Talzenna combination therapy for castration-sensitive prostate cancer, surpassing Johnson & Johnson. This article delves into the implications of this breakthrough for the pharmaceutical landscape.
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is talazoparib?
talazoparib (TALZENNA) is a poly [adp-ribose] polymerase 2 inhibitor. Associated with Pfizer Australia Pty Ltd.
What is the brand name for talazoparib?
TALZENNA is a marketed brand name for talazoparib. Check FDA Drugs@FDA for the current US label holder and prescribing information.